



Elena Rodica Gafton

str. G.ral Mathias Berthelot nr 2-4, 700483, Iasi, România

● EXPERIENȚA PROFESIONALĂ

06/2019 – ÎN CURS – Iasi, România

MEDIC PRIMAR ONCOLOGIE MEDICALA (ORDIN MS NR. 17652/IUNIE 2019) – INSTITUTUL REGIONAL DE ONCOLOGIE IAȘI

Activitate medicala de specialitate, cercetare medicala

28/01/2014 – 30/06/2019 – Iasi, România

MEDIC SPECIALIST ONCOLOGIE MEDICALA (ORDIN MS NR 3909 / 27. JAN 2014) – INSTITUTUL REGIONAL DE ONCOLOGIE IAȘI

Activitate medicala de specialitate, cercetare medicala

● EDUCAȚIE ȘI FORMARE PROFESIONALĂ

2009 – 2013 – Iasi, România

MEDIC REZIDENT ONCOLOGIE MEDICALA – Universitatea de Medicina și Farmacie 'Grigore T. Popa' Iași

2002 – 2008 – Iasi, România

DOCTOR-MEDIC – Universitatea de Medicina și Farmacie 'Grigore T. Popa' Iași

Domeniul (domeniile) de studiu

◦ Medicina generala

● COMPETENȚE LINGVISTICE

Limbă(i) maternă(e): ROMÂNĂ

Altă limbă (Alte limbi):

	COMPREHENSIUNE		VORBIT		SCRIS
	Comprehensiune orală	Citit	Exprimare scrisă	Conversație	
ENGLEZĂ	C2	C1	B2	C1	B2
FRANCEZA	B2	B1	B1	B1	B1

Niveluri: A1 și A2 Utilizator de bază B1 și B2 Utilizator independent C1 și C2 Utilizator experimentat

● COMPETENȚE DIGITALE

Microsoft Office Word | Microsoft Office Excel | Microsoft Office PowerPoint | Navigare Internet | Utilizare buna a programelor de comunicare(mail messenger skype) | Microsoft PowerPoint | Google Drive | SPSS | Zoom

● **PUBLICAȚII**

Evaluation of Tumor Response to Systemic Therapy in Hepatocellular Carcinoma

Revista Medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2012, Vol. 116, Nr. 4
2012

Administrarea agentilor terapeutici în cancer, ed II

Iași: Ed. Pim, 2015. [330 pages, ISBN 978-606-13-2878-9]
2016
Miron L, Marinca M, Gafton B, Alexa T, Pruteanu C, Murgulet E, Postolache E.

Porocarcinoma: a rare cause of lateral cervical tumor

Archive of Clinical Cases
www.clinicalcases.eu – 2019
Gabriela Maria Aniței*, Nicolae Șerban Ioanid , Geanina Bandol , Elena Rodica Gafton , Ana Maria Patrașcu , Dan Ferariu , Angelica Slătineanu, Gema Bugean , Viorel Scripcariu

● **CONFERINȚE ȘI SEMINARE**

05/2012 – 05/2012 – Dubrovnik, Croatia,
The 2nd Balkan and Eastern European Masterclass in Clinical Oncology,

09/2014 – 09/2014 – Viena
Perceptorship Lung Cancer

01/10/2015 – 31/10/2015 – The Christie Hospital Manchester
ACP Precision Oncology Workshop; internship

13/02/2020 – 14/02/2020 – Champalimaud Centre , Lisbon
Game of Thrones in Rectal Cancer

● PROIECTE

2011 – 2013

STUDII CLINICE

2011

- HGS 1012-C1103: Systemic Treatment for Hepatocellular Cancer, Clinical Phase of Trial: III, Role in Trial: Sub-Investigator

2012

- PALO 10-01: Antiemetic for High Emetogenic Chemotherapy based on Cisplatin, Clinical Phase of Trial: III, Role in Trial: Sub-Investigator

- NETU 08-18: Antiemetic for High Emetogenic Chemotherapy based on Anthracyclines and Cyclophosphamide, Clinical Phase of Trial: III, Role in Trial: Sub-Investigator

2013

- Merck V212-011: A Phase III, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of V212 in Adults with Solid Tumor or Hematologic Malignancy, Role in Trial: Sub-Investigator

- 9090-14 GALAXY 2 Study : A Randomized, Phase III Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma, Role in Trial: Sub-Investigator

- Galena Biopharma PH3-01: Phase III, controlled multicenter, multinational, prospective, randomized, double-blind study to assess the efficacy and safety of NeuVaxTM in subjects with early stage Node Positive breast cancer whose tumors express low or intermediate levels of the HER2 protein, Role in Trial: Study Coordinator

- CRAD001YIC04: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine prior endocrine therapy, investigating the treatment of everolimus (TAD001) in combination with exemestane. Role in Trial: Sub-Investigator

BO28407: A randomized, multicenter, open-label, phase III trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as adjuvant therapy in patients with operable Her2-positive primary breast cancer . Role in Trial: Study Coordinator

2015 – ÎN CURS

STUDII CLINICE

2015

MK3475-PN042 : MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer. Role in Trial: Sub-Investigator

- BI 1200.217: An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an EGFR mutation (Del19 or L858R) who have failed first-line treatment with platinum-based chemotherapy.

2016

- SOLAR-1; CBYL719C2301A Phase III randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment (SOLAR-1;NCT02437318).

- A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive-Disease Stage Small-cell Lung Cancer (ED-SCLC) after Completion of Platinum based First Line Chemotherapy

2017

- A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab in Combination with Ipilimumab, versus Nivolumab in Combination with Ipilimumab Placebo in Subjects with recurrent or metastatic squamous cell carcinoma of head and neck – CheckMate714- SI

2018

- A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma - SI

2019

- ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)- SI

- A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer- SI

2015

MK3475-PN042 : MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer. Role in Trial: Sub-Investigator

- BI 1200.217: An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an EGFR mutation (Del19 or L858R) who have failed first-line treatment with platinum-based chemotherapy.

2016

- SOLAR-1; CBYL719C2301A Phase III randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment (SOLAR-1;NCT02437318).

- A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive-Disease Stage Small-cell Lung Cancer (ED-SCLC) after Completion of Platinum based First Line Chemotherapy

2017

- A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab in Combination with Ipilimumab, versus Nivolumab in Combination with Ipilimumab Placebo in Subjects with recurrent or metastatic squamous cell carcinoma of head and neck – CheckMate714- SI

2018

- A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma - SI

2019

- ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)- SI

-A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer- SI

● **COMPETENȚE ORGANIZATORICE**

Departament Spitalizare de zi

Capacitate de lucru în echipa

Abilitati interpersonale

Capacitate de organizare și planificare

Abilitati de comunicare, calm